ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
BP profits hit nearly $5bn in three months
BP PLC (LSE: BP.) has reported an increase in first-quarter profit, reflecting strong oil and gas trading. The oil major stated that its underlying replacement cost profit for the first
ANGLE reports that its order book remains robust, citing 2022 as a year of significant progress.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
Angle PLC Pharma Services Contract with Crescendo Biologics
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has signed an agreement with Crescendo Biologics, a clinical-stage immuno-oncology company, to offer its advanced Portrait Flex Assay, a liquid biopsy tool, for a
BP has been accused of committing “serious violations” following a deadly explosion at a refinery in the United States.
According to the safety regulator, inadequate operations and training were factors that led to an accident resulting in the death of two workers.
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA